Phoenix, Arizona--(Newsfile Corp. - November 17, 2020) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (OTCQX: LXRP) ("the Company"), known for its proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the Company's proprietary drug delivery technology, DehydraTECH™. "That's our patented technology; we now have close to 20 patents granted," shared Bunka. "We have 50 to 60 patents pending all over the world," he added. "DehydraTECH™ is wholly owned. This is something that we developed under our roof," said Bunka. "It's a method by which we can process many drugs, like CB, nicotine, cannabinoids, vitamins, and many different substances, before you swallow them," he explained. Bunka then shared that processing these substances improves the taste, while also delivering the drug quickly and more effectively. "DehydraTECH™ delivers a much higher fraction of the drug, a much higher proportion," said Bunka before elaborating on the results of clinical studies proving its effectiveness.
Jolly then asked about the Company's additional projects and focuses. Bunka shared that the Company has formal business relationships with two of the largest tobacco companies in the world, including the owners of Marlboro. "If they decide to use our technology for non-combusted forms of nicotine, not for cigarettes, they have to pay us a royalty," shared Bunka. "About three months ago, we also announced a relationship with British American Tobacco (BAT)," continued Bunka, adding that BAT sells combusted and non-combusted nicotine products in over 100 different countries.
"What Lexaria is trying to do with nicotine is use our DehydraTECH™ technology to help deliver the nicotine in an oral form with no smoke, no lung disease," explained Bunka. "Even the FDA has come out as recently as a year ago and said that some oral forms of nicotine have a reduced health risk compared to combusted forms."
Bunka then elaborated on the Company's additional projects, including their work with cannabidiol and antiviral drugs. "There is a lot going on with the company and all of those things and more remain very much targets of ours for the next 6,9, and 12 months."
The conversation then turned to the Company's first patent in Europe, which was announced on October 21st, 2020. "That was patent #18 overall," shared Bunka. "We have patents granted now in both America and Australia," he added. "In Australia, about a year ago, we received a patent that allowed us to use the technology with CBD to treat heart disease," said Bunka. "Just a few weeks ago, we received a similar but broader and more important patent for Europe," he shared, adding that this patent will allow the Company to use DehydraTECH™ with CBD, as well as other substances, to treat conditions like heart disease, alzheimer's, schizophrenia, and Parkinson's disease.
"We've already filed the paperwork to repeat that patent in America," said Bunka. "That really starts to change our company into a pharma or biotech company, which is something we're trying to achieve."
Jolly then asked about the Company's impressive projections for the fourth quarter. "We set-up a facility that can implement our technology into what we call 'buckets of powder', which contain CBD and our technology is already implemented," said Bunka. "Then we sell that bulk ingredient to other businesses, and they incorporate the powder into their final products," he said. "That business is growing by leaps and bounds," shared Bunka. "It's grown by roughly 1,000% in 12 months," he added. "Quarter-by-quarter, we're expecting multi-hundred percent growth moving forward."
"We have been informed by our corporate clients to expect that they will give us orders for calendar 2021 of well in excess of 50 million servings," said Bunka. "We're talking about really incredible growth rates for us."
To close the interview, Bunka shared the Company's stock is currently near an all-time low for the last several years, making it a valuable consideration for investors. He also shared that the Company has continued to increase their intellectual property, and is currently conducting research in the antiviral sector while also moving forward with their nicotine division. "The markets that we're looking at are worth tens of billions of dollars each," explained Bunka. "We're not like a lot of companies our size because we partner with Fortune 500 companies and have demonstrated our ability," he said, adding that the Company also plans to uplist in the near future. "There are lots of catalysts coming here that should produce more value for our shareholders."
To hear Chris Bunka's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7731886-lexaria-bioscience-corp-discusses-the-significance-of-their-intellectual-property-with-the-stock.
Lexaria Bioscience Corp.'s (OTCQX: LXRP) (CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
This release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company related to strategic plans for 2021 and successfully executing its four core areas of business focus. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, collaborating with third parties or selling any products containing any active ingredient or drug. There is no assurance that any planned corporate activity, research and development, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful: industry-wide, these initiatives often fail and, in some cases, may require amendments, revisions or repeating as appropriate to reach successful outcomes. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part or be defensible. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
Stock Day Media
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68374